Smith+Nephew Cuts FY26 Guidance as US Hips and Knees Lag; J&J Depuy Talks Ended
SNN sits 16% above its 52-week low of $26.12.
Summary
Smith+Nephew cut FY26 guidance to around 3% revenue growth and around $1,250 million of trading profit on weak US Hips and Knees, and confirmed its approach to J&J over a Depuy Synthes combination has ended without a deal.
Key Events · Earnings and Guidance · SNN
-
Q3 Revenue Grows 3.4% to $1,551M
Q3 2026 revenue was $1,551 million versus $1,501 million a year earlier, 3.4% growth on both an underlying and reported basis. Sports Medicine & ENT rose 8.0% and Advanced Wound Devices 10.7%, while Orthopaedics grew 2.5% underlying.
-
FY26 Guidance Cut Across the Board
Underlying revenue growth guidance falls to around 3% from around 4%, trading profit growth to around 4% from around 8%, and trading profit to around $1,250 million from around $1,300 million. Free cash flow drops to around $750 million from around $800 million and adjusted ROIC to around 9% from more than 10%.
-
US Knees and Hips Still Contracting
US Knee Implants revenue fell 7.3% and US Hip Implants 1.0%, both on an underlying and reported basis. Management attributed the knee decline mainly to business lost in prior periods plus market softness, and said CATALYSTEM set deployment pace is limiting hip customer conversions.
-
J&J Depuy Synthes Discussions Ended
The Board confirmed it approached Johnson & Johnson earlier in the year about a possible combination of its Orthopaedics business with Depuy Synthes, and that those conversations have now ended. The company said it will keep exploring strategic options for the unit.
Analysis · SNN · Industrial Applications And Services
Full-year revenue growth guidance drops to around 3% from around 4%, and trading profit growth to around 4% from around 8% — roughly $1,250 million of trading profit instead of around $1,300 million. The shortfall is concentrated in US Hips and Knees, where Q3 US knee revenue fell 7.3% and CATALYSTEM set deployment is limiting hip conversions. Separately, the company confirmed it approached Johnson & Johnson about combining its Orthopaedics unit with Depuy Synthes and that those talks have ended, leaving the portfolio question open with no deal in hand. Sports Medicine grew 8.0% and Advanced Wound Devices 10.7%, so the problem is narrow but it is the segment the market has been waiting to see fixed.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNN was trading at $30.34 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $26.12 to $37.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.